

#22
7.16-03

Express Mail No. EV 335 855 927 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: *Jove et al.*

Confirmation No.: 1344

Serial No.: 09/492,764

Art Unit: 1642

Filed: January 27, 2000

Examiner: Rawlings, S.

For: INHIBITION OF STAT3 SIGNAL
TRANSDUCTION FOR HUMAN CANCER
THERAPY

Attorney Docket No: 10873-008-999
(formerly 114205.1101)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUL 07 2003

Sir:

TECH CENTER 1600/2900

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith several pages of a "revised form PTO-1449" entitled "List of References Cited by Applicant". Legible copies of References AA- CI are being submitted herewith. For References AE and AF, which are pending patent applications, copies of the applications as filed and claims as pending are enclosed.


Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application. While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicants particularly direct the Examiner's attention to references AD, AH, AI, AO, AS, BZ, CA, CB, CF, and CG.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, the fee

required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date June 30, 2003

 32,605
Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090